Acrux Says Europe Marketing Authorization for Recuvyra Granted

Acrux Ltd. (ACR) said the European Medicines Agency has granted the marketing authorization for commercial use of Recuvyra 50 mg/mL transdermal solution for dogs, according to a regulatory filing.

To contact the editor responsible for this story: Victoria Batchelor at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.